ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business.
Terms of the Agreement
This Bristol Myers Squibb deal is the latest one that it has signed in less than a week. It has just announced its purchase of Karuna Therapeutics, a drug developer, on Friday, as per Reuters.
With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share of RayzeBio.
Looking Forward to Growth as Bristol Myers and RayzeBio Merge
Bristol Myers Squibb's acquisition of RayzeBio is a strategic move that aligns with the recent gush of mergers and acquisition agreements in the pharmaceutical industry. The companies' respective management teams believe this deal will fuel growth within the second half of this decade.
"This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond," Bristol Myers Squibb's chief executive officer, Christopher Boerner, Ph.D., said in a press release. "We look forward to supporting and accelerating RayzeBio's preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform."
RayzeBio's president and CEO, Ken Song, M.D., further stated, "Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy."
The biotech firm's chief added, "Bristol Myers Squibb's well-established presence in oncology and deep expertise in developing, commercializing, and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution and I am very excited to see what our team clinches as part of Bristol Myers Squibb."
Photo by: Bristol Myers Squibb Media Gallery
